21.41% More Acasti Pharma Inc – Class A (NASDAQ:ACST) Short Interest

Acasti Pharma Inc. (NASDAQ:ACST) Corporate Logo

It was showed an increase on Acasti Pharma Inc – Class A (NASDAQ:ACST)’s shorted shares with 21.41%. It was issued in December by FINRA the 520,500 shorted shares on ACST. Previously was reported up change of 21.41% from 428,700 shares. With Average volume 172,400, ACST’s previous position will take 3 days to restore.

The stock decreased 1.71% or $0.0116 during the last trading session, hitting $0.6658.Acasti Pharma Inc. has volume of 361,251 shares. Since December 8, 2017 ACST has declined 57.02% and is downtrending. ACST underperformed the S&P500 by 72.64%.

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases.The firm is valued at $52.56 million. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia.Currently it has negative earnings.

For more Acasti Pharma Inc. (NASDAQ:ACST) news brought out briefly go to: Benzinga.com, Marketwired.com, Marketwired.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “24 Stocks Moving In Tuesday’s Pre-Market Session – Benzinga” brought out on October 02, 2018, “Acasti Expands Global Patent Portfolio with Newly Granted Patents in South Korea and Canada – Marketwired” on January 04, 2018, “Acasti Pharma Clarifies Term of Proposed Strategic Partnership with Leading China Pharmaceutical Company – Marketwired” with a publish date: November 22, 2017, “Acasti Pharma Appoints Donald Olds to its Board of Directors and Audit Committee – GlobeNewswire” and the last “Acasti Pharma Provides Clinical and Market Update TSX Venture Exchange:ACST – GlobeNewswire” with publication date: September 18, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.